BIAF
NASDAQ HealthcarebioAffinity Technologies, Inc. - Common Stock
Diagnostics & Research
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
�� 市场数据
| 价格 | $9.43 |
|---|---|
| 成交量 | 10,341,835 |
| 市值 | 5.66M |
| 贝塔系数 | -1.110 |
| RSI（14日） | 57.1 |
| 200日均线 | $21.63 |
| 50日均线 | $8.35 |
| 52周最高 | $109.35 |
| 52周最低 | $4.56 |
| Forward P/E | -15.72 |
| Price / Book | 1.13 |
🎯 投资策略评分
BIAF 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (98/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 💰 Dividend Daddy (23/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 BIAF in your text
粘贴任何文章、记录或帖子 — 工具将提取 BIAF 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-09-18.